Scinai Immunotherapeutics Ltd.

Nasdaq:SCNI

Biological Products, (No Diagnostic Substances)·JERUSALEM, L3

Summary Financials

Revenue

$658,000

FY 2024

Adj. EBITDA

-$10.6M

-1609.4% margin

FY 2024

Net Income

-$5.8M

-880.9% margin

FY 2024

EPS (Diluted)

$0.01

FY 2024

Stock Price

$0.71

-5.3%

2026-03-13

52W Range

$0.61 – $6.18

P/E Ratio

71.0x

Market Cap

$2.4B

Cash

$14.1M

FY 2024

Total Debt

$375,000

FY 2022

Net Cash

$13.7M

FY 2022

Enterprise Value

$2.4B

Debt / EBITDA

1.3x

FY 2024

EV / EBITDA

-227.5x

Employees

—

Revenue

$658,000

FY 2024

Adj. EBITDA

-$10.6M

-1609.4% margin

FY 2024

Net Income

-$5.8M

-880.9% margin

FY 2024

EPS (Diluted)

$0.01

FY 2024

Stock Price

$0.71

-5.3%

2026-03-13

52W Range

$0.61 – $6.18

P/E Ratio

71.0x

Market Cap

$2.4B

Cash

$14.1M

FY 2024

Total Debt

$375,000

FY 2022

Net Cash

$13.7M

FY 2022

Enterprise Value

$2.4B

Debt / EBITDA

1.3x

FY 2024

EV / EBITDA

-227.5x

Employees

—